Trial · NCT01631812
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters. | SPM 962 | Any AEs | 126 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters. | SPM 962 | Treatment-Related AEs | 112 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters. | SPM 962 | SAEs including death | 17 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters. | SPM 962 | Severe AEs | 12 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters. | SPM 962 | Discontinuation due to AEs | 26 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters. | SPM 962 | Severe laboratory abnormality | 10 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters. | SPM 962 | ≥30 mmHg decrease* | 6 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters. | SPM 962 | Treatment-related AE of orthostatic hypotension | 6 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters. | SPM 962 | QTcB ≥500 ms | 1 | participants | |
| Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score | SPM 962 | Week 12 | -9.6 | Standard Deviation 8.1 | Scores on a scale |
| Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score | SPM 962 | Week 24 | -9.1 | Standard Deviation 8.2 | Scores on a scale |
| Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score | SPM 962 | Week 52 | -8.3 | Standard Deviation 9.8 | Scores on a scale |
| UPDRS Part 2 Sum Score | SPM 962 | Week 12 | -2.7 | Standard Deviation 3.5 | Scores on a scale |
| UPDRS Part 2 Sum Score | SPM 962 | Week 24 | -2.4 | Standard Deviation 3.7 | Scores on a scale |
| UPDRS Part 2 Sum Score | SPM 962 | Week 52 | -1.9 | Standard Deviation 4.7 | Scores on a scale |
| Absolute Time Spent Off | SPM 962 | Week 12 | -3.0 | Standard Deviation 2.7 | Hours |
| Absolute Time Spent Off | SPM 962 | Week 24 | -2.6 | Standard Deviation 2.9 | Hours |
| Absolute Time Spent Off | SPM 962 | Week 52 | -1.9 | Standard Deviation 3.0 | Hours |
| Skin Irritation Score of the Application Site | SPM 962 | - | 18 | participants | |
| Skin Irritation Score of the Application Site | SPM 962 | ± | 53 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01631812/results